NHS Tayside has now considered your request dated 12 June 2019.

NHS Tayside wishes to advise you that there are exemptions applicable to the information requested. Please refer to the exemptions section of this correspondence.

Extract from Request

1. “Does your trust treat adult multiple myeloma [MM]? Yes.

2. If yes, then how many MM patients, have been treated in the past 6 months with the following:
   - Bortezomib [Velcade] 10
   - Carfilzomib [Kyprolis] Nil
   - Ixazomib [Ninlaro] <5
   - Lenalidomide [Revlimid] 55
   - Daratumumab [Darzalex] <5
   - Melphalan, prednisolone and thalidomide (known as MPT) <5
   - Cyclophosphamide, thalidomide and dexamethasone (known as CTD) 10
   - Pomalidomide [Imnovid] <5

3. If you are able to split by therapy line for question 2, please indicate the number of patients above being treated, 1st line and 2nd line. Information not held.

4. Does your trust treat adult/paediatric primary immune thrombocytopenia patients [ITP]? Yes.

5. If yes, then of the treated adult/paediatric primary immune thrombocytopenia patients, how many are on the following:
   - Eltrombopag [Revolade] 11
   - Romiplostim [Nplate] 6


7. Do you treat patients with a Thrombopoietin Receptor Agonist TPO for the following diseases –

7a. Chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy
   - Eltrombopag [Revolade] No.
   - Romiplostim [Nplate] No.
7b. Acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation
  - Eltrombopag [Revolade] No.
  - Romiplostim [Nplate] No.

7c. Chemotherapy induced thrombocytopenia (CIT)
  - Eltrombopag [Revolade] No.
  - Romiplostim [Nplate] No.
  - 7d myelodysplastic syndromes (MDS) No.
  - Eltrombopag [Revolade] No.
  - Romiplostim [Nplate] No.

8. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated? 26

9. If possible how many CLL patients treated were new to therapy in the past 3 months? 6

10. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following:
  - Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR) <5
  - Bendamustine and rituximab (known as BR) <5
  - Ibrutinib [Imbruvica] 11
  - Chlorambucil Nil
  - Venetoclax 6
  - Obinutuzumab <5
  - Idelalisib Nil
  - Fludarabine and rituximab (known as FR) Nil
  - High-dose prednisone and rituximab Nil
  - Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR) Nil
  - Alemtuzumab (Campath) with rituximab” Nil

Response

Please see response above in black bold. All responses relate to secondary care only.

Where the values of statistics provided fall below 5 but are greater than 0, these statistics are represented by ‘<5’. Due to the small numbers of patients involved further detail cannot be provided as disclosure of the information may lead to the identification of individuals.

<table>
<thead>
<tr>
<th>Document Ref.</th>
<th>FOISA Exemption Applied</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGTFOISA6400</td>
<td>Section 17 – Information not held (Q3).</td>
<td>NHS Tayside does not hold the information requested.</td>
</tr>
<tr>
<td></td>
<td>Section 38 (1)(a) – Personal information (Q2).</td>
<td>Information relating to an individual is personal information. Disclosure of information which would allow the identification of individuals would be in breach of confidentiality and Data Protection principles.</td>
</tr>
</tbody>
</table>
Under section 20 (1) of the Act, if you are dissatisfied with the way NHS Tayside has dealt with your request, you have a right to request a review of our actions and decisions in relation to your request, and you have a right to appeal to the Scottish Information Commission.

A request for an internal review must be made in writing no later than forty working days from receipt of this response and sent to:

Head of Information Governance
Maryfield House (South)
30 Mains Loans
Dundee
DD4 7BT

Or by email to informationgovernance.tayside@nhs.net

If you are not content with the outcome of the internal review, you have the right to apply directly to the Scottish Information Commissioner for a decision. The Scottish Information Commissioner can be contacted at:

Scottish Information Commissioner
Kinburn Castle
Doubledykes Road
St Andrews, Fife
KY16 9DS

Or via the online appeal service: www.itsonpublicknowledge.info/Appeal

If you have any queries about this correspondence, please contact:

Information Governance Team
Maryfield House
30 Mains Loan
Dundee
DD4 7BT

Telephone - 01382 424413
E-mail: informationgovernance.tayside@nhs.net

Information Governance
NHS Tayside
25 June 2019